02 Jul 2015

Rocephin vials (Ceftriaxone) - United Kingdom

ATC: J01DD
ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
THIRD-GENERATION CEPHALOSPORINS
Rocephin vials

Last Updated on 02 Jul 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Rocephin vials Indication

Rocephin is indicated for the treatment of the following infections in adults and children including term neonates (from birth):

Bacterial Meningitis

Community acquired pneumonia

Hospital acquired pneumonia

Acute otitis media

Intra-abdominal infections

Complicated urinary tract infections (including pyelonephritis)

Infections of bones and joints

Complicated skin and soft tissue infections

Gonorrhoea

Syphilis

Bacterial endocarditis

Rocephin may be used:

For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults

For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III)) in adults and children including neonates from 15 days of age.

For Pre-operative prophylaxis of surgical site infections

In the management of neutropenic patients with fever that is suspected to be due to a bacterial infection

In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above

Rocephin should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum.

Consideration should be given to official guidelines on the appropriate use of antibacterial agents.

 

Rocephin vials Generic Name

Ceftriaxone

Type

POM

Summary Product Characteristics (SPCs) Links
SPC - Rocephin 250mg, 1g and 2g vials (external site)

Related Learning Zones

Hypogonadism Knowledge Centre

Hypogonadism Knowledge Centre

The Hypogonadism Knowledge Centre provides healthcare professionals with free access to disease awareness sections such as epidemiology, pathophysiology, signs and symptoms, treatment options to assist the process of diagnosis, treatment and monitoring of patients with the condition. The regularly updated publications digest area contains analysis and comment on recent scientific articles related to male hypogonadism.

G.MKT.GM.MH.01.2016.0364

IL-17A in Psoriasis Knowledge Centre

IL-17A in Psoriasis Knowledge Centre

IL-17A in Psoriasis is intended for healthcare professionals involved in the treatment and management of patients with psoriasis. This resource has been developed primarily to discuss the role of the IL-17 pathway in the pathogenesis of psoriasis and the therapeutic potential of treatments directed towards IL-17A. Users can expect to find sections containing expert videos, clinical slide decks, congress highlights, key publications and links to useful resources.

This resource has been developed in collaboration with Novartis Pharma AG.

Rocephin vials Marketing Information

Rocephin vials Generic Name
Ceftriaxone
Marketing Company
Roche Products Limited
Drug Type
POM
Date of Issue, Marketing Authority 23/10/2003

Related Drugs - Infectious Diseases

Back to top